Bookmark and Share
BioAssay: AID 743127

Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds

Name: Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds. ..more
_
   
 Tested Compounds
 Tested Compounds
All(2)
 
 
Inactive(2)
 
 
 Tested Substances
 Tested Substances
All(2)
 
 
Inactive(2)
 
 
 Related BioAssays
 Related BioAssays
AID: 743127
Data Source: The Scripps Research Institute Molecular Screening Center (HELACYTOX_INH_ABS_3XCC50)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
BioAssay Version:
Deposit Date: 2013-11-26
Hold-until Date: 2014-08-09
Modify Date: 2014-08-09

Data Table ( Complete ):           View All Data
Tested Compounds:
Related Experiments
Show more
AIDNameTypeProbeComment
2174Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).Screening depositor-specified cross reference: Primary screen (LYPLA1 inhibitors in singlicate)
2177Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).Screening depositor-specified cross reference: Primary screen (LYPLA2 inhibitors in singlicate)
2202Summary of probe development efforts to identify inhibitors of lysophospholipase 1 (LYPLA1).Summary2 depositor-specified cross reference: Summary (LYPLA1 inhibitors)
2203Summary of probe development efforts to identify inhibitors of lysophospholipase 2 (LYPLA2).Summary1 depositor-specified cross reference: Summary (LYPLA2 inhibitors)
2232Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2).Screening depositor-specified cross reference: Confirmation screen (LYPLA2 inhibitors in triplicate)
2233Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of lysophospholipase 1 (LYPLA1).Screening depositor-specified cross reference: Confirmation screen (LYPLA1 inhibitors in triplicate)
493105Assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition of recombinant and endogenous enzymeOther depositor-specified cross reference: Confirmation screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
493108Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: fluorescence-based cell-based inhibitionOther depositor-specified cross reference: Late stage screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
493109Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: LC-MS/MS assay to assess binding of compounds to active siteOther depositor-specified cross reference: Late stage LCMS assay (LYPLA1)
493110Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: Gel-based Activity-Based Protein Profiling (ABPP) IC50 for LYPLA1 and LYPLA2Confirmatory depositor-specified cross reference: Late stage dose response (LYPLA1 and LYPLA2 inhibitors in triplicate)
493111Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther depositor-specified cross reference: Late stage screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
493154Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Gel-based Activity-Based Protein Profiling (ABPP) IC50 for off-target ABHD11Confirmatory depositor-specified cross reference: Late stage dose response counterscreen (ABHD11 inhibitors in triplicate)
493161Late stage assay provider results from the probe development effort to identify dual inhibitors of LYPLA1 and LYPLA2: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compoundsConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (T-cell cytotoxicity in quadruplicate)
504482Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based cell-based gel-based Activity-Based Protein Profiling (ABPP) IC50 for anti-target ABHD11Confirmatory depositor-specified cross reference: Late stage dose repsonse (ABHD11 inhibitors in triplicate)
504498Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: LC-MS/MS assay to assess binding of compounds to active site of anti-target ABHD11Other depositor-specified cross reference: Late stage MOA assay (ABDH11 LCMS)
504505Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based cell-based gel-based Activity-Based Protein Profiling (ABPP) percent inhibition for anti-target ABHD11Other depositor-specified cross reference: Late stage screen (ABHD11 inhibitors in singlicate, in situ)
504507Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based biochemical gel-based Activity-Based Protein Profiling (ABPP) IC50 for anti-target ABHD11 Set 2Confirmatory depositor-specified cross reference: Late stage dose response (ABHD11 inhibitors in triplicate)
504510Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds set 2Confirmatory depositor-specified cross reference: Late stage dose repsonse counterscreen (T-cell cytotoxicity in quadruplicate)
504520Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: fluorescence-based biochemical gel-based Activity-Based Protein Profiling (ABPP) inhibition and selectivityOther depositor-specified cross reference: Late stage screen (LYPLA1 and LYPLA2 inhibitors in singlicate)
504522Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: LC-MS-based cell-based SILAC Activity-Based Protein Profiling (ABPP) for anti-target ABHD11Other depositor-specified cross reference: Late stage (LC-MS-based cell-based SILAC ABPP for anti-target ABHD11)
504892Late stage assay provider results from the probe development effort to identify inhibitors of ABHD11: Fluorescence-based biochemical gel-based Activity-Based Protein Profiling (ABPP) inhibition of the human isoform of ABHD11Other depositor-specified cross reference: Late stage assay (human isoform of ABHD11 inhibitors)
651978Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitroOther depositor-specified cross reference: Late stage ABPP in vitro SILAC assay (LYPLA 1)
651979Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situOther depositor-specified cross reference: Late stage ABPP in situ SILAC assay (LYPLA 1)
651980Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situOther depositor-specified cross reference: Late stage assay (SILAC selectivity analysis in situ)
651981Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitroOther depositor-specified cross reference: Late stage assay (SILAC selectivity analysis in vitro)
651985Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivoOther depositor-specified cross reference: Late stage assay (LYPLA1 and LYPLA2 inhibitors activity in vivo)
651986Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in situOther depositor-specified cross reference: Late stage assay (LYPLA1 and LYPLA2 inhibitors activity in situ)
651987Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess binding modeOther depositor-specified cross reference: Late stage assay (binding mode)
651988Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther depositor-specified cross reference: Late stage assay (inhibition and selectivity)
651990Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPPConfirmatory depositor-specified cross reference: Late stage dose-response (LYPLA1 and LYPLA2 inhibitors in triplicate)
651991Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compoundsConfirmatory depositor-specified cross reference: Late stage dose-response (cytotoxicity 6 replicates)
651998Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: Substrate-based fluorescence-based biochemical determination of kinetic parametersConfirmatory depositor-specified cross reference: Late stage ABPP biochemical kinetics assay (LYPLA 1)
652001Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Substrate-based fluorescence-based biochemical determination of kinetic parametersConfirmatory depositor-specified cross reference: Late stage assay (LYPLA2 kinetic parameters in quadruplicate)
652003Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: fluorescence-based biochemical dose-response assayConfirmatory depositor-specified cross reference: Late stage ABPP biochemical dose response assay (LYPLA 1) (4XIC50)
652004Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: fluorescence-based biochemical dose-response assayConfirmatory depositor-specified cross reference: Late stage dose response (LYPLA2 inhibitors in quadruplicate)
652018Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2Other depositor-specified cross reference: Late stage assay (LYPLA1 and LYPLA2 inhibition and selectivity in singlicate)
2143Summary of probe development efforts to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).Summary3 same project related to Summary assay
652029Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibitionOther same project related to Summary assay
652030Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther same project related to Summary assay
743117Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition potency and selectivityOther same project related to Summary assay
743118Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitroConfirmatory same project related to Summary assay
743119Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in situConfirmatory same project related to Summary assay
743132Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro in mouse brainConfirmatory same project related to Summary assay
743133Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess inhibitor binding modeOther same project related to Summary assay
743134Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP assay to assess in vivo activityOther same project related to Summary assay
2143Summary of probe development efforts to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).Summary3 same project related to Summary assay
652029Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibitionOther same project related to Summary assay
652030Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityOther same project related to Summary assay
743117Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition potency and selectivityOther same project related to Summary assay
743118Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitroConfirmatory same project related to Summary assay
743119Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in situConfirmatory same project related to Summary assay
743132Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro in mouse brainConfirmatory same project related to Summary assay
743133Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess inhibitor binding modeOther same project related to Summary assay
743134Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP assay to assess in vivo activityOther same project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Benjamin Cravatt, TSRI
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 CA132630
Grant Proposal PI: Benjamin Cravatt, TSRI
External Assay ID: HELACYTOX_INH_ABS_3XCC50

Name: Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds.

Description:

Protein palmitoylation is an essential post-translational modification necessary for trafficking and localization of regulatory proteins that play key roles in cell growth and signaling. Numerous proteins have been identified as targets of palmitoylation, including cytoskeletal proteins, kinases, receptors, and other proteins involved in various aspects of cellular signaling and homeostasis [1]. Using a global chemo-proteomic method for the metabolic incorporation and identification of palmitoylated proteins, we were able to identify hundreds of palmitoylated proteins, revealing palmitoylation as a widespread post-translational modification (PTM) [2]. Palmitoylation involves an acyl-thioester linkage to specific cysteines [3,4]. Given the labile properties of thioesters, palmitoylation is potentially reversible and may be regulated in a manner analogous to other PTMs (e.g., phosphorylation). As such, identification of proteins responsible for the dynamic modulation of palmitoylation is paramount to understanding its patho/physiological roles. For example, multiple oncogenes, including HRAS and SRC, require palmitoylation for malignant transformation [5], suggesting protein palmitoyl thioesterases may have tumor suppressor activity required to repress aberrant growth signaling. More than a decade ago, the cytosolic serine hydrolase acyl-protein thioesterase 1 (APT1) was identified as an in vitro HRAS palmitoyl thioesterase [6]. Initially classified as lysophospholipase 1 (LYPLA1) [7], the enzyme has since been demonstrated to have several hundred-fold higher activity as a protein thioesterase. While the in vitro data [6,8] provided an intriguing clue to its possible role in vivo, prior to our studies, little was known about the in vivo thioesterase activity of LYPLA1. Upon retroviral shRNA knockdown of LYPLA1, we found that HRAS was robustly hyper-palmitoylated, providing the first evidence that the endogenous enzyme is a functional protein palmitoyl thioesterase capable of regulating HRAS palmitoylation in mammalian cells. However, shRNA resulted in only an 80% reduction in LYPLA1 expression (unpublished). LYPLA2 (a.k.a. APT2) is 65% identical to LYPLA1, and also exhibits lysophospholipase activity in vitro, but its potential role as a thioesterase is unknown [9]. shRNA knockdown studies of LYPLA2 revealed only partial knockdown of the enzyme, making substrate identification inconclusive (unpublished). A principle goal of post-genomic research is the determination of the molecular and cellular role of uncharacterized enzymes like LYPLA1 and LYPLA2. As such, selective inhibitors of LYPLA1 and/or LYPLA2 would greatly aid investigations into the biological function of these enzymes. Several inhibitors of LYPLA1 have been described [10,11], but none of these agents have proven capable of inhibiting LYPLA1 activity in cells. We recently reported optimization of a covalent dual LYPLA1/LYPLA2 inhibitor ML211 (SID 99445338), and identification of reversible compounds ML348 (SID 160654487) and ML349 (SID 160654496) that act as selective LYPLA1 and LYPLA2 inhibitors, respectively (see Probe Reports on the NIH Bookshelf at http://www.ncbi.nlm.nih.gov/books/NBK47352/). These compounds represent an important advance in chemical tools for investigating the biological function(s) of LYPLA1 and LYPLA2. However, ML211 (SID 99445338), owing to its modest solubility, does not have demonstrated in vivo activity. Irreversible chemical probes have distinct advantages vs. reversible compounds for use in living systems, as confirming target engagement is a comparatively straightforward process, and near-complete and sustained target inhibition can be achieved without extensive optimization of physicochemical and pharmacokinetic properties. The goal of this current investigation is to develop an irreversible, in vivo-active dual LYPLA1/LYPLA2 inhibitor to add to the arsenal of available chemical tools for identification of LYPLA1 and LYPLA2 substrates and evaluating the role of these enzymes in dynamic de-palmitoylation and tumorigenesis.

References:

1. Dekker, F.J., et al., Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat. Chem. Biol., 2010. 6(6): p. 449-56.
2. Duncan, J.A. and A.G. Gilman, A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein alpha subunits and p21(RAS). J. Biol. Chem., 1998. 273(25): p. 15830-7.
3. Sugimoto, H., H. Hayashi, and S. Yamashita, Purification, cDNA cloning, and regulation of lysophospholipase from rat liver. J. Biol. Chem., 1996. 271(13): p. 7705-11.
4. Toyoda, T., H. Sugimoto, and S. Yamashita, Sequence, expression in Escherichia coli, and characterization of lysophospholipase II. Biochim. Biophys. Acta, 1999. 1437(2): p. 182-93.
5. Biel, M., et al., Synthesis and evaluation of acyl protein thioesterase 1 (APT1) inhibitors. Chemistry, 2006. 12(15): p. 4121-43.
6. Deck, P., et al., Development and biological evaluation of acyl protein thioesterase 1 (APT1) inhibitors. Angew. Chem. Int. Ed. Engl., 2005. 44(31): p. 4975-80.
7. Jessani, N., et al., Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. U. S. A., 2002. 99(16): p. 10335-40.
8. Leung, D., et al., Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol., 2003. 21(6): p. 687-91.
9. Bachovchin, D.A., et al., Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes. Nat. Biotechnol., 2009. 27(4): p. 387-94.
10. Forner, F., et al., Quantitative proteomic comparison of rat mitochondria from muscle, heart, and liver. Mol. Cell. Proteomics, 2006. 5(4): p. 608-19.
11. Schubert, C., The genomic basis of the Williams-Beuren syndrome. Cell. Mol. Life Sci., 2009. 66(7): p. 1178-97.

Keywords:

late stage, late stage AID, assay provider, powders, LYPLA1, lysophospholipase 1, LYPLA2, lysophospholipase 2, APT1, acyl-protein thioesterase 1, APT2, acyl-protein thioesterase 2, serine hydrolase, palmitoylation, counterscreen, dose response, HeLa, cell-based, WST-1, formazan, viability, cytotoxicity, CC50, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Panel Assay with Multiple Targets/Outcomes
PID§NameSubstancePanel TargetsDescription
ActiveInactive
1Viability in serum-free medium2
2Viability in serum-supplemented medium2

§ Panel component ID.
Protocol
Assay Overview:

The purpose of this assay is to determine cytotoxicity of powder samples of test compounds. In this assay, HeLa cells in either serum-free medium (Assay 1) or medium containing fetal calf serum (FCS) (Assay 2) are incubated with test compounds, followed by determination of cell viability. The assay utilizes the WST-1 substrate which is converted into colorimetric formazan dye by the metabolic activity of viable cells. The amount of formed formazan directly correlates to the number of metabolically active cells in the culture. As designed, compounds that reduce cell viability will result in decreased absorbance of the dye. Compounds are tested in triplicate in a 5-point 1:10 dilution series starting at a nominal concentration of 100 uM.

Protocol Summary:

This assay was started by seeding HeLa cells in DMEM medium supplemented with 10% FCS and 1X Pen-Strep-Glutamine in a 96-well plate. Cells were incubated at 37 degrees Celsius in a humidified incubator until 80% confluent (24 hours). Medium was removed and 100 uL of fresh medium (serum-free or supplemented with 10% FCS), pre-mixed with DMSO or test compound, was added to each well. Cells were incubated for 48 hours at 37 degrees Celsius in a humidified incubator and cell viability was determined by the WST-1 assay (Roche) according to manufacturer instructions. CC50 values were determined from dose-response curves from three replicates at each inhibitor concentration (100, 10, 1, 0.1, 0.01 uM).

The % cell viability for each well was calculated as follows:

%_Cell_Viability = ( ABS_Test_Compound - MedianABS_Low_Control ) / ( MedianABS_High_Control - MedianABS_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing cells in the presence of test compound.
High_Control is defined as wells containing cells treated with media only (no compound).
Low_Control is defined as wells containing no cells (media only).

Assay Outcome:

Compounds with CC50 values less than 10 uM were considered active (cytotoxic). Compounds with CC50 values greater than or equal to 10 uM were considered inactive (non-cytotoxic).

PubChem Activity Outcome:

Compounds active in Assay 1 and/or Assay 2 were considered active (cytotoxic). Compounds inactive in both Assay 1 and Assay 2 were considered inactive (non-cytotoxic).

List of Reagents:

HeLa cells (provided by the Assay Provider)
DMEM Medium (CellGro 10-017-CV)
FCS (Omega Scientific, FB-01)
1x PenStrep Glutamine (CellGro 30-002-CI)
WST-1 reagent (Roche)
96-well plates (Corning)
Comment
This assay was performed by the assay provider with powder samples of synthetic test compounds.
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Outcome [Serum-free medium]One of Active or Inactive1Outcome
2Qualifier [Serum-free medium]Activity Qualifier identifies if the resultant CC50 came from a fitted curve or was determined manually to be greater than or approximately equal to its listed CC50 concentration.1String
3CC50 [Serum-free medium]*The concentration at which 50 percent viability in the assay is observed; (CC50) shown in micromolar.1FloatμM
4Viability in Serum-free medium at 0.01 uM [1] (0.01μM**)Value of % Cell Viability at 0.01 uM compound concentration.1Float%
5Viability in Serum-free medium at 0.01 uM [2] (0.01μM**)Value of % Cell Viability at 0.01 uM compound concentration.1Float%
6Viability in Serum-free medium at 0.01 uM [3] (0.01μM**)Value of % Cell Viability at 0.01 uM compound concentration.1Float%
7Viability in Serum-free medium at 0.1 uM [1] (0.1μM**)Value of % Cell Viability at 0.1 uM compound concentration.1Float%
8Viability in Serum-free medium at 0.1 uM [2] (0.1μM**)Value of % Cell Viability at 0.1 uM compound concentration.1Float%
9Viability in Serum-free medium at 0.1 uM [3] (0.1μM**)Value of % Cell Viability at 0.1 uM compound concentration.1Float%
10Viability in Serum-free medium at 1 uM [1] (1μM**)Value of % Cell Viability at 1 uM compound concentration.1Float%
11Viability in Serum-free medium at 1 uM [2] (1μM**)Value of % Cell Viability at 1 uM compound concentration.1Float%
12Viability in Serum-free medium at 1 uM [3] (1μM**)Value of % Cell Viability at 1 uM compound concentration.1Float%
13Viability in Serum-free medium at 10 uM [1] (10μM**)Value of % Cell Viability at 10 uM compound concentration.1Float%
14Viability in Serum-free medium at 10 uM [2] (10μM**)Value of % Cell Viability at 10 uM compound concentration.1Float%
15Viability in Serum-free medium at 10 uM [3] (10μM**)Value of % Cell Viability at 10 uM compound concentration.1Float%
16Viability in Serum-free medium at 100 uM [1] (100μM**)Value of % Cell Viability at 100 uM compound concentration.1Float%
17Viability in Serum-free medium at 100 uM [2] (100μM**)Value of % Cell Viability at 100 uM compound concentration.1Float%
18Viability in Serum-free medium at 100 uM [3] (100μM**)Value of % Cell Viability at 100 uM compound concentration.1Float%
19Outcome [Serum-supplemented medium]One of Active or Inactive2Outcome
20Qualifier [Serum-supplemented medium]Activity Qualifier identifies if the resultant CC50 came from a fitted curve or was determined manually to be greater than or approximately equal to its listed CC50 concentration.2String
21CC50 [Serum-supplemented medium]*The concentration at which 50 percent viability in the assay is observed; (CC50) shown in micromolar.2FloatμM
22Viability in Serum-supplemented medium at 0.01 uM [1] (0.01μM**)Value of % Cell Viability at 0.01 uM compound concentration.2Float%
23Viability in Serum-supplemented medium at 0.01 uM [2] (0.01μM**)Value of % Cell Viability at 0.01 uM compound concentration.2Float%
24Viability in Serum-supplemented medium at 0.01 uM [3] (0.01μM**)Value of % Cell Viability at 0.01 uM compound concentration.2Float%
25Viability in Serum-supplemented medium at 0.1 uM [1] (0.1μM**)Value of % Cell Viability at 0.1 uM compound concentration.2Float%
26Viability in Serum-supplemented medium at 0.1 uM [2] (0.1μM**)Value of % Cell Viability at 0.1 uM compound concentration.2Float%
27Viability in Serum-supplemented medium at 0.1 uM [3] (0.1μM**)Value of % Cell Viability at 0.1 uM compound concentration.2Float%
28Viability in Serum-supplemented medium at 1 uM [1] (1μM**)Value of % Cell Viability at 1 uM compound concentration.2Float%
29Viability in Serum-supplemented medium at 1 uM [2] (1μM**)Value of % Cell Viability at 1 uM compound concentration.2Float%
30Viability in Serum-supplemented medium at 1 uM [3] (1μM**)Value of % Cell Viability at 1 uM compound concentration.2Float%
31Viability in Serum-supplemented medium at 10 uM [1] (10μM**)Value of % Cell Viability at 10 uM compound concentration.2Float%
32Viability in Serum-supplemented medium at 10 uM [2] (10μM**)Value of % Cell Viability at 10 uM compound concentration.2Float%
33Viability in Serum-supplemented medium at 10 uM [3] (10μM**)Value of % Cell Viability at 10 uM compound concentration.2Float%
34Viability in Serum-supplemented medium at 100 uM [1] (100μM**)Value of % Cell Viability at 100 uM compound concentration.2Float%
35Viability in Serum-supplemented medium at 100 uM [2] (100μM**)Value of % Cell Viability at 100 uM compound concentration.2Float%
36Viability in Serum-supplemented medium at 100 uM [3] (100μM**)Value of % Cell Viability at 100 uM compound concentration.2Float%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R01 CA132630

PageFrom: